MedinCell SA (MEDCL) AI Stock Analysis

• Market Cap: €1.25B
• Dividend Yield: N/A
• Average Volume (3M): 179.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: 181.43%
• EPS Growth: 28.76%
• Country: FR
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 33,098,885
• 10 Day Avg. Volume: 204,359
• 30 Day Avg. Volume: 179,664
• PEG Ratio: 0.80
• Price to Book (P/B): -25.60
• Price to Sales (P/S): 16.41
• P/FCF Ratio: 23.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €34.30
• Price Target Upside: 21.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: €27.00 ▼(-4.12% Downside)

MedinCell SA's overall score is primarily impacted by its financial instability and weak technical indicators. While revenue growth is strong, profitability issues and high leverage pose significant risks. The negative P/E ratio further detracts from its valuation appeal.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for MedinCell's innovative drug delivery systems, supporting long-term business expansion and market penetration.

Partnership Revenue Model

The partnership-based revenue model provides financial stability and market access, enhancing MedinCell's ability to scale and innovate in the biotechnology sector.

Positive Operating Cash Flow

Positive operating cash flow suggests effective cash management, providing MedinCell with the liquidity needed to invest in R&D and sustain operations despite profitability challenges.

Negative Factors

High Leverage

High leverage indicates financial risk, potentially limiting MedinCell's ability to invest in growth opportunities and increasing vulnerability to economic downturns.

Negative Equity

Negative equity highlights financial instability, which could impact MedinCell's ability to secure financing and sustain long-term operations.

Profitability Challenges

Ongoing profitability challenges reflect operational inefficiencies, which may hinder MedinCell's ability to generate sustainable earnings and reinvest in business growth.

MedinCell SA Business Overview & Revenue Model

Company Description

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.

How the Company Makes Money

MedinCell generates revenue through a combination of collaborative partnerships, licensing agreements, and product sales. The company partners with pharmaceutical companies to develop and commercialize its drug delivery solutions, often receiving upfront payments, milestone payments based on development progress, and royalties from product sales. These collaborations are crucial as they provide funding for research and development while sharing the financial risks associated with bringing new therapies to market. MedinCell's revenue model is further supported by its ability to create a diverse portfolio of products targeting unmet medical needs, enhancing its attractiveness to potential partners and investors.

MedinCell SA Financial Statement Overview

Summary

MedinCell SA shows strong revenue growth but struggles with profitability and financial stability. High leverage and negative equity are concerning, though positive operating cash flow offers some relief.

Income Statement

MedinCell SA has shown significant revenue growth of 93.49% in the latest year, indicating strong top-line expansion. However, the company is struggling with profitability, as evidenced by negative net profit margins (-72.19%) and EBIT margins (-51.64%). The consistent negative margins highlight ongoing operational challenges and cost management issues.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of -3.59, indicating significant leverage and potential financial risk. The negative stockholders' equity suggests that liabilities exceed assets, which is a concerning sign of financial instability. Return on equity is positive at 112.65%, but this is due to negative equity, which distorts the metric.

Cash Flow

The cash flow statement shows a decrease in free cash flow growth (-15.33%), but the company has managed to generate positive operating cash flow. The free cash flow to net income ratio of 0.91 suggests that the company is generating cash relative to its net losses, which is a positive aspect amidst overall cash flow challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.20M	25.54M	9.16M	9.94M	4.09M	8.19M
Gross Profit	12.87M	25.54M	9.16M	9.94M	4.09M	6.74M
EBITDA	-18.81M	-11.20M	-18.61M	-26.41M	-21.45M	-15.38M
Net Income	-31.45M	-18.44M	-25.04M	-32.01M	-24.81M	-19.02M
Balance Sheet
Total Assets	58.86M	90.45M	36.95M	29.34M	44.30M	63.61M
Cash, Cash Equivalents and Short-Term Investments	38.85M	71.90M	19.46M	6.47M	26.59M	49.87M
Total Debt	59.60M	58.76M	58.96M	57.71M	47.49M	43.34M
Total Liabilities	112.89M	106.82M	77.77M	71.63M	57.67M	54.69M
Stockholders Equity	-54.03M	-16.37M	-40.82M	-42.29M	-13.37M	8.92M
Cash Flow
Free Cash Flow	21.03M	17.80M	-13.11M	-22.03M	-23.34M	-12.96M
Operating Cash Flow	21.40M	19.46M	-11.92M	-21.00M	-21.36M	-12.14M
Investing Cash Flow	-7.42M	-13.21M	-613.00K	1.30M	-316.00K	-1.06M
Financing Cash Flow	-9.13M	33.32M	25.53M	1.56M	-800.00K	47.92M

MedinCell SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28.16
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MEDCL, the sentiment is Negative. The current price of 28.16 is below the 20-day moving average (MA) of 30.70, below the 50-day MA of 30.28, and above the 200-day MA of 19.45, indicating a neutral trend. The MACD of -0.90 indicates Positive momentum. The RSI at 38.95 is Neutral, neither overbought nor oversold. The STOCH value of 31.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:MEDCL.

MedinCell SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABVX	55 Neutral	€6.87B	-31.59	―	―	―	18.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DBV	50 Neutral	€470.02M	-2.76	-241.12%	―	―	3.09%
NANO	49 Neutral	€832.03M	-23.55	―	―	―	―
IVA	47 Neutral	€536.06M	-0.98	―	―	-12.84%	-81.94%
VLA	46 Neutral	€683.56M	-9.63	-55.53%	―	13.48%	-1299.09%
MEDCL	42 Neutral	€1.25B	-60.46	―	―	181.43%	28.76%